Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polymyocytoid, also known as Polyinosinic:polycytidylic acid or Poly I:C, is a synthetic double-stranded RNA (dsRNA) polymer that functions as an immunostimulant. It is used as an injection and acts by activating pattern recognition receptors such as Toll-like receptor 3 (TLR3) in endosomal compartments and Melanoma differentiation-associated protein 5 (MDA-5) in the cytoplasm. This activation leads to the production of type I interferons and other cytokines, enhancing immune responses and inducing apoptosis in cancer cells. Polymyocytoid is also recognized for its broad-spectrum antiviral properties and its ability to stimulate the reticuloendothelial system, thereby improving overall immune function and macrophage phagocytic activity. It is being investigated for its role in treating recurrent/metastatic liver cancer and has historically been used for viral infections like viral keratitis, herpes simplex, and as an auxiliary treatment for chronic viral hepatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polymyocytoid.